HK1012267A1 - Use of topotecan in the treatment of non-small cell lung carcinoma - Google Patents

Use of topotecan in the treatment of non-small cell lung carcinoma

Info

Publication number
HK1012267A1
HK1012267A1 HK98113537A HK98113537A HK1012267A1 HK 1012267 A1 HK1012267 A1 HK 1012267A1 HK 98113537 A HK98113537 A HK 98113537A HK 98113537 A HK98113537 A HK 98113537A HK 1012267 A1 HK1012267 A1 HK 1012267A1
Authority
HK
Hong Kong
Prior art keywords
small cell
cell lung
lung carcinoma
topotecan
treatment
Prior art date
Application number
HK98113537A
Other languages
English (en)
Inventor
Randall Keith Johnson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HK1012267A1 publication Critical patent/HK1012267A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
HK98113537A 1991-02-21 1998-12-15 Use of topotecan in the treatment of non-small cell lung carcinoma HK1012267A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65893791A 1991-02-21 1991-02-21
PCT/US1992/001034 WO1992014471A1 (en) 1991-02-21 1992-02-07 Treatment of non-small cell lung carcinoma

Publications (1)

Publication Number Publication Date
HK1012267A1 true HK1012267A1 (en) 1999-07-30

Family

ID=24643331

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98113537A HK1012267A1 (en) 1991-02-21 1998-12-15 Use of topotecan in the treatment of non-small cell lung carcinoma

Country Status (14)

Country Link
US (1) US5756512A (xx)
EP (1) EP0572549B1 (xx)
JP (1) JP2738979B2 (xx)
KR (1) KR930702984A (xx)
AT (1) ATE227991T1 (xx)
AU (2) AU1531992A (xx)
CA (1) CA2103707C (xx)
DE (1) DE69232852T2 (xx)
DK (1) DK0572549T3 (xx)
ES (1) ES2187500T3 (xx)
HK (1) HK1012267A1 (xx)
MX (1) MX9200755A (xx)
PT (1) PT100155B (xx)
WO (1) WO1992014471A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Also Published As

Publication number Publication date
ES2187500T3 (es) 2003-06-16
US5756512A (en) 1998-05-26
DK0572549T3 (da) 2003-01-06
KR930702984A (ko) 1993-11-29
EP0572549A1 (en) 1993-12-08
AU1531992A (en) 1992-09-15
AU4042795A (en) 1996-02-22
WO1992014471A1 (en) 1992-09-03
JPH06505741A (ja) 1994-06-30
EP0572549B1 (en) 2002-11-20
JP2738979B2 (ja) 1998-04-08
CA2103707C (en) 2003-12-09
DE69232852T2 (de) 2003-09-04
EP0572549A4 (xx) 1994-01-12
PT100155A (pt) 1993-05-31
DE69232852D1 (de) 2003-01-02
CA2103707A1 (en) 1992-08-22
ATE227991T1 (de) 2002-12-15
PT100155B (pt) 1999-09-30
AU699436B2 (en) 1998-12-03
MX9200755A (es) 1992-08-01

Similar Documents

Publication Publication Date Title
HK1012268A1 (en) Composition containing cisplatin and topotecan as antitumor agent
HK1022422A1 (en) Immune response modifier compounds for treatment of th2 mediated and related diseases
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
IE900250L (en) Immunogenic compositions against gastrin peptides
HK1022810A1 (en) Method of treating endothelial injury
HU9402914D0 (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
MY106528A (en) Method of treating impotence.
GB9223552D0 (en) Improvements in or relating to the treatment of effluents
DE3478749D1 (en) Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism
HK1012267A1 (en) Use of topotecan in the treatment of non-small cell lung carcinoma
DE3569673D1 (en) Use of saccharomyces yeasts for the manufacture of a medicament for preventing or treating pseudo-membranous colitis
GR3023645T3 (en) Treatment of liver cancer
IL131478A0 (en) Methods for treatment of scar tissue
CA2103708A1 (en) Treatment of ovarian cancer
ES2012547A6 (es) Procedimiento para preparar una composicion farmaceutica que contiene metaloporfirinas.
KR0177821B1 (en) Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans
IL89998A0 (en) Use of gonadoliberin derivatives in the treatment of tumours
AR244180A1 (es) Mejoras en dispositivos para el tratamiento de agua, con gases oxidantes producidos ''in situ''.
GB8818556D0 (en) Novel therapeutic immunoconjugates for use in treatment of cancer
BG34201A1 (en) Method for potentiating the effect of cytostatic agents in chemical treatment of cancer
MX9706404A (es) Metodo para tratar deplecion de adenosina.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100207